All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2018-11-16.
From the record
Utah Medical Products, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2018-11-16) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-0.2% a year over 10 filed years; profitable in 10 of 10.
From the record
Utah Medical Products, Inc.'s 10 filed years say what it did: revenue went from $39 million in fiscal 2016 to $39 million in fiscal 2025, down 0.2% a year; it rose in 5 of 9 years; the deepest fall was 26% from fiscal 2022 to fiscal 2025; net income was positive in 10 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count shrank 3.8% a year. 79% of cash flow returned. Insiders: 0 sales, 1 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Utah Medical Products, Inc.'s diluted share count shrank about 3.8% a year, and dividends and buybacks returned about 79% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 1 purchase of their own stock on the open market in the year to 2026-10-29, buying about $67 thousand (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 9%: 9¢ of profit per shareholder dollar. Leverage 3%: owes 3¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Utah Medical Products, Inc. earned about 9 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 18 cents per dollar of everything the company owns. Leverage: it owed about 3 cents per dollar of assets, and net share issuance: its share count shrank 7.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 49% of 109 in its family; net margin 29.3%.
From the record
Utah Medical Products, Inc.'s standing among 109 graded names in its industry family: revenue of $39 million in fiscal 2025 ranks in the bottom 36% by size; a net margin of 29.3% ranks in the top 2%; revenue growth of -9.7% a year over the last 3 filed years ranks in the bottom 14% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 17% of 91 in its family for leadership; chief executive since 2006.
From the record
Utah Medical Products, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Cornwell, Kevin L (Chairman, CEO, as filed), filing under that title since 2006-01-04, 20.9 years (top 1% of its family); the 4 officers and directors filing in the last fifteen months have been on the record a median of 14.7 years (top 3%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 4 people in charge now (top 48%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 40% of 104 in its family for room to expand.
From the record
Utah Medical Products, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $86 million against debt of $0 thousand leaves 70% of its assets as net cash, top 9% of its family; cash from operations less capital spending is 37.2% of revenue (top 1%); a gross margin of 57.1% (bottom 45%); research spending of 1.7% of revenue (bottom 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 33% of 105 in its family for growth drivers.
From the record
Utah Medical Products, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -9.7% a year over the last three filed years against -0.2% over all 10, slowing (bottom 26% of its family); the newest year grew -5.8% (bottom 17%); research spending grew 10.7% a year (top 34%); capital spending grew -22.9% a year (bottom 23%) (its annual reports). Utah Medical Products, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 41% of 88 in its family for expectations against reality.
From the record
Utah Medical Products, Inc.'s newest year against its own record: revenue of $39 million in fiscal 2025 came in 6.5% above the $36 million its prior three years' pace pointed to (top 19% of its family); net income of $11 million against a prior three-year average of $16 million (bottom 24%); a net margin of 29.3% against 32.8% before (bottom 16%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made